Distribution and Clinical Implication of CMD in Patients With HFpEF Without Significant CAD (HFpEF-CMD)
Distribution and Clinical Implication of Coronary Flow Reserve and Index of Microcirculatory Resistance in Patients With Heart Failure With Preserved Ejection Fraction Without Significant Coronary Artery Disease
Sponsor: Samsung Medical Center
This observational or N/A phase trial investigates Coronary Microvascular Dysfunction and Heart Failure With Preserved Ejection Fraction and is currently ongoing. Samsung Medical Center leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Recruiting
-
Sep 2024 — Sep 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Feb 2022 — Feb 2024 [monthly]
Recruiting
-
Apr 2021 — Feb 2022 [monthly]
Recruiting
First recorded
Jan 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .